Vertex Pharmaceuticals Inc / MA (VRTX)
Vertex Pharmaceuticals Inc / MA (VRTX) is a Healthcare stock tracked by StreetAlpha. VRTX reports earnings on Mon, Nov 2, 2026. The average 12-month price target from 10 analysts is $552.90, with a high of $665.00 and a low of $350.00. Analyst consensus is Buy, based on the latest ratings from 10 firms (8 buy, 1 hold, 1 sell). Over the past 90 days StreetAlpha recorded 10 whale options trades in VRTX, 50% of them bullish and 50% bearish. In the past 30 days there were 8 dark pool prints totaling $9.3M, the largest $3.0M.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →Based on 10 analysts who set a price target on VRTX in the past 90 days. The average target is $552.90, with a high of $665.00 and a low of $350.00.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 28 | UBS | Target raised | Buy | $585 → $615 |
| Sep 11 | JP Morgan | Reinstated | Buy | $560 |
| Sep 2 | Morgan Stanley | Reinstated | Buy | $665 |
| Aug 5 | Truist Securities | Target raised | Buy | $560 → $565 |
| Aug 5 | Barclays | Maintained | Buy | $617 |
Whale Options Flow
90DDark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VRTX is in one of them and how their past VRTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered VRTX in an article yet. Here's the latest on the wider market.
For informational purposes only. Not financial advice. Options flow and dark pool data are delayed and may be incomplete.